NTRK2 and central nervous system cancer: Combined molecular groups based on the presence or absence of the four tumor markers (IDH status, 1p19q co-deletion status and CHI3L1 and NTRK2 expression levels) were used to classify the 671 glioma cases in the TCGA cohort according to prognosis.